Supplementary Table 2 Definition and assessment of measured outcomes

Author, year

Time of assessment

Reincke, 199245

Unclear, mean follow up 28 (18-60) months Unclear, mean follow up of 38 (12-63) months

Rossi, 200047

Hypertension

Overweight/obesity

Pre-diabetes / diabetes mellitus

Dyslipidemia

Definition of disease Not defined

Definition of improvement Decrease in the dose, number or discontinuation of medications

Definition of disease Not defined

Definition of improvement Weight loss of more than 5 kg

Definition of disease Not defined

Definition of improvement Improvement resulting in switch to diet therapy only

Definition of disease Not reported

Definition of improvement Not reported

Mild/ moderate/seve re 46

Decrease in the dose, number or discontinuation of medications

BMI ≥25 kg/m2

Not reported

DM: Fasting glucose > 126 mg/dL or glucose intolerance47

Reduction of oral medications or insulin

Not reported

Morioka, 200042 Midorikawa , 200139

Not reported 1 month

Not defined

Not defined

Not defined

Not defined

Not defined

Not defined

Total cholesterol > 240 mg/dL; LDL > 160 mg/dL; and/or triglycerides > 160 mg/dL Not defined

Not defined

Individual SBP and DBP measurements

Not defined

Not defined

Not defined

Not reported

Not reported

Bernini, 200331

12 months

SBP≥140 mmHg ± DBP≥ 90 mmHg or on medications

Normalization and “improvement” in BP

Overweight BMI 2529.9, obese > 30 kg/m2

Not defined

OGTT: Diabetes = 0 glucose > 7.7 mmol/l +/ 120 minute glucose > 15.4mmol; Normal 0 glucose < 6.05 60 < 8.8 and 120 minute < 6.6 mmol. Per AACE guidelines48

Normalization and “improvement” of IFG/DM, not otherwise defined

Not reported

Not reported

BMI > 30 kg/m2

“improvement ” not defined pre/post means for Fasting glucose

IFG: Fasting glucose > 110mg/dL, DM: >126 or medications

Cessation of medications or insulin

Total cholesterol >200 mg/dL, LDL>130 mg/dL, trigs > 150 mg/dL; HDL30 obese.

BMI drop to 126 mg/dL IFG: Fasting glucose > 110mg/dL Or on medications Not defined

Izaki, 200634

Not reported

Mitchell, 200740

Not reported

Feng, 200732 Tsuiki, 200849

Sereg, 200948

9.1 +/-3.1 years

SBP≥140 mmHg ± DBP≥ 90 mm Hg or on medications

Not reported

Not reported

Normalization or improvement was decided based on withdrawal or reduction of medication dose Not defined

Not reported

Not reported

Not defined

Not defined

Normoglycemia (glucose 0.3% or discontinuation /decrease of medications Normalization or improved based on withdrawal or reduction of medication dose (oral or insulin)

Total cholesterol >220 mg/dL, or on medications

total cholesterol decrease to 150 mg/dL, HDL 30kg/m2 obese

Giordano, 201023

Not reported

SBP≥125 mmHg ± DBP≥ 80 mmHg

Not defined

overweight / obesity > 25 kg/m2

Chiodini, 201019

18 months

SBP≥135 mmHg ± DBP≥ 85 mmHg or on medications

Change of HTN grade (European Society Cardiology49 Mean SBP and DBP before and after

BMI > 30 kg/m2

Miyazato, 201141

Not reported

SBP≥150 mmHg ± DBP≥ 90 mm Hg

Not defined

BMI ≥25 kg/m2

Mean BMI before and after surgery, n “improved” Before and after mean BMI/SDs P values and magnitude of change reported Not defined

on OGTT > 7.0 mmol or 120 minute > 11.1 mmol; IGT if 120 minute glucose 7.811.0 mmol Not defined

> 2.6 mmol / TG > 1.7 mmol

Not defined

Not defined

Not reported

DM: Fasting glucose > 126 mg/dL IFG: Fasting glucose > 110mg/dL

P values and magnitude of change reported to fasting plasma glucose

TG ≥ 150, HDL 150 mg/dL; Total cholesterol > 240 mg/dL

Not defined

Improvement = greater than 5% decrease in body weight Body weight before and after mean

type 2 DM by WHO criteria or if on diabetic medication

TG ≥ 150 mg/dL, HDL 110mg/dL

Fasting plasma glucose considered changed if move from one category to another according to Adult Treatment Panel III criteria50 Fasting plasma glucose mean before and after Normalization or “improvement” not defined Mean Hb A1c pre/post

Hyperlipidemia if TG ≥ 172 mg/dL or Total cholesterol. >220 mg/dL or if on statin.

Not defined.

Akaza, 201129

Unclear, mean follow up 28±7 months for surgical and 40±19 months for nonsurgical groups

SBP≥140 mmHg ± DBP≥ 90 mmHg or on medications

Decrease in BP 30 kg/m2

weight decrease by ≥ 3 kg

Or on medications Or HbA1c>6.1% DM: Fasting glucose > 126 mg/dL or 2h glucose after 75 g oral glucose >200 mg/dL or HbA1C>6.1% or on medications IFG: Fasting glucose > 110mg/dL, 2h glucose after 75 g oral glucose 140-199 mg/dL

Normoglycemia (glucose 0.3% or discontinuation /decrease of medications

LDL>140 mg/dL, trigs > 150 mg/dL; HDL 126 mg/dL IFG: Fasting glucose > 110mg/dL

Defined as TG ≥ 150 mg/dL HDL 110mg/dL

Change in glucose level

Kawate, 201436

5.3 years

SBP≥140 mmHg ± DBP≥ 90 mm Hg or on medications

Decrease in BP 126 mg/dL or random glucose >200 mg/dL or HbA1C>6.5% or on medications IFG: Fasting glucose > 110mg/dL or random glucose 140199 mg/dL

Normalization or amelioration of laboratory data, or decrease in the dose, number or discontinuation of medications

Papierska, 201443 Kang, 201535

At least 6 months Average follow up 34.5 months

Not defined Not defined

Decrease in the dose, number or discontinuation of medications or improved control on the same medications

Not defined

Not defined

Not reported

Not defined

TG >150 mg/dL = hyperTG, HDL